Bito L Z, Wallenstein M, Baroody R
Adv Prostaglandin Thromboxane Res. 1976;1:297-303.
Currently available evidence shows that some cell membranes represent a barrier to passive diffusion of PGs. In contrast, an active transport of PGs was demonstrated across the wall of the rabbit vagina in vitro. Evidence has been obtained indicating that similar carrier-mediated PG transport processes in vivo mediate the uptake of PGs from the circulation into the lung and the removal of these autocoids from the brain and the eye, across the blood--brain and blood--aqueous barriers. It was shown that probenecid, a known inhibitor of PG transport, enhances the effect of PGE1 on the brain, and in general, it appears to alter the distribution and rate of excretion of PGs. The existence of such barriers to the free diffusion of PGs and the saturable, and possibly rate-limiting, transport of these autocoids across some other membranes must be taken into consideration in the design of experiments and in the interpretation of results. Furthermore, the importance of this consideration is emphasized by the observation that many nonsteroidal antiinflammatory agents and PG antagonists are effective inhibitors of PG transport (17,18); hence, they can be expected to affect the distribution and disposition of PGs.
目前可得的证据表明,一些细胞膜对前列腺素(PGs)的被动扩散构成障碍。相比之下,体外实验证明PGs可通过兔阴道壁进行主动转运。已有证据表明,体内类似的载体介导的PG转运过程介导了PGs从循环系统进入肺部,以及这些自体活性物质从大脑和眼睛穿过血脑屏障和血房水屏障的清除过程。研究表明,丙磺舒是一种已知的PG转运抑制剂,它能增强PGE1对大脑的作用,总体而言,它似乎会改变PGs的分布和排泄速率。在设计实验和解释结果时,必须考虑到PGs自由扩散的此类屏障的存在,以及这些自体活性物质在其他一些膜上的可饱和且可能限速的转运。此外,许多非甾体抗炎药和PG拮抗剂是PG转运的有效抑制剂这一观察结果强调了这一考虑的重要性(17,18);因此,可以预期它们会影响PGs的分布和处置。